GT
MRNA icon

Greenleaf Trust’s Moderna MRNA Stock Holding History

Greenleaf Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
4,964
-712
-13% -$36.8K ﹤0.01% 627
2026
Q1 		$288K Buy
+5,676
New +$265K ﹤0.01% 667
2025
Q1 		– Sell
-5,244
Closed -$218K – 819
2024
Q4 		$218K Buy
5,244
+1,739
+50% +$83.1K ﹤0.01% 757
2024
Q3 		$234K Sell
3,505
-1,894
-35% -$174K ﹤0.01% 746
2024
Q2 		$641K Buy
5,399
+2,146
+66% +$272K 0.01% 413
2024
Q1 		$347K Buy
3,253
+953
+41% +$96.1K ﹤0.01% 567
2023
Q4 		$229K Sell
2,300
-485
-17% -$40.8K ﹤0.01% 679
2023
Q3 		$288K Sell
2,785
-307
-10% -$34.2K ﹤0.01% 589
2023
Q2 		$376K Sell
3,092
-425
-12% -$56.7K ﹤0.01% 529
2023
Q1 		$540K Sell
3,517
-1,547
-31% -$255K 0.01% 428
2022
Q4 		$910K Buy
5,064
+2,251
+80% +$368K 0.01% 282
2022
Q3 		$333K Sell
2,813
-217
-7% -$32.9K ﹤0.01% 505
2022
Q2 		$433K Buy
3,030
+111
+4% +$15.9K 0.01% 448
2022
Q1 		$503K Buy
2,919
+192
+7% +$32.3K 0.01% 416
2021
Q4 		$693K Sell
2,727
-741
-21% -$217K 0.01% 331
2021
Q3 		$1.33M Buy
+3,468
New +$1.28M 0.02% 178

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Greenleaf Trust's MRNA Position: Q2 2026 in Review

Greenleaf Trust reduced its Moderna (MRNA) stake by 13% in Q2 2026, selling an estimated $36.8K and leaving 4,964 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #627.

Greenleaf Trust first reported a position in MRNA in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.33M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Greenleaf Trust held 4,964 shares of Moderna worth $348K as of Q2 2026.
  • Greenleaf Trust sold 712 Moderna shares in Q2 2026, an estimated $36.8K.
  • Moderna made up ﹤0.01% of Greenleaf Trust's portfolio in Q2 2026, its #627 holding.
  • Greenleaf Trust first reported a position in Moderna in Q3 2021 and has held it in 16 quarters since.
  • Greenleaf Trust's Moderna position peaked at $1.33M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.